S'abonner

Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy?: data from the CaPSURE database - 05/09/11

Doi : 10.1016/S0090-4295(00)00705-6 
Gary D Grossfeld a, , James J Chang a, Jeanette M Broering a, Dave P Miller b, Jenny Yu b, Scott C Flanders c, Peter R Carroll a, 1
a Department of Urology, University of California, San Francisco, Urology Outcomes Research Group and University of California, San Francisco/Mount Zion Cancer Center, University of California, San Francisco, California, San Francisco, California, USA 
b Lewin-TAG, Inc., San Francisco, California, USA 
c TAP Holdings Inc., Deerfield, Illinois, USA 

*Reprint requests: Gary D. Grossfeld, M.D., Department of Urology, U-575, University of California, San Francisco, 533 Parnassus, San Francisco, CA 94143-0738

Abstract

Objectives. To determine whether more complete sampling of the radical prostatectomy (RP) specimen better predicts outcome after surgery.

Methods. We reviewed pathology reports from 1383 patients enrolled in CaPSURE (a longitudinal registry of patients with prostate cancer) who underwent RP. Specimens were considered step-sectioned only if the entire specimen was submitted for analysis and if sections were taken at 0.5-cm intervals or less. Otherwise, specimens were considered non-step-sectioned. Pathologic stage, Gleason score, surgical margin status, and outcome were compared between groups. Prostate-specific antigen (PSA) recurrence was defined as a PSA level of 0.2 ng/mL or greater on two consecutive occasions after RP. Secondary cancer treatment consisted of radiation or androgen deprivation after RP. Adjuvant treatments occurred within 6 months of RP, and nonadjuvant treatments occurred more than 6 months after RP. Kaplan-Meier event rates of PSA recurrence and secondary treatment were calculated for patients in the step-sectioned and non-step-sectioned groups.

Results. No significant differences were found between patients in the step-sectioned and non-step-sectioned groups with respect to pathologic tumor stage, prostatectomy Gleason score, or margin status. Patients in whom step-sectioning was performed had a lower serum PSA at diagnosis than patients in the non-step-sectioned group. When examining all patients, no differences were observed in the use of secondary treatments or PSA recurrence based on the method of pathologic analysis. However, patients with negative margins in whom step-sectioning was performed exhibited significantly lower secondary nonadjuvant treatment use and appeared to have a lower risk of PSA recurrence than similar patients in the non-step-sectioned group.

Conclusions. These data suggest that more complete pathologic analysis of the surgical specimen may better predict outcome for some patients undergoing RP. Additional research is warranted to determine whether such differences justify the additional resources necessary to recommend routine step-sectioning.

Le texte complet de cet article est disponible en PDF.

Plan


 This study was supported by an educational grant from TAP Holdings, Inc.


© 2000  Elsevier Science Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 56 - N° 3

P. 430-435 - septembre 2000 Retour au numéro
Article précédent Article précédent
  • Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy
  • Shahrokh F Shariat, Franco Bergamaschi, Howard L Adler, Cuong Nguyen, Michael W Kattan, Thomas M Wheeler, Kevin M Slawin
| Article suivant Article suivant
  • Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present
  • P.F Schellhammer, R Moriarty, D Bostwick, D Kuban

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.